These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau. Wilson EN, Swarovski MS, Linortner P, Shahid M, Zuckerman AJ, Wang Q, Channappa D, Minhas PS, Mhatre SD, Plowey ED, Quinn JF, Zabetian CP, Tian L, Longo FM, Cholerton B, Montine TJ, Poston KL, Andreasson KI. Brain; 2020 Mar 01; 143(3):932-943. PubMed ID: 32065223 [Abstract] [Full Text] [Related]
43. REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson's disease: a cross-sectional and longitudinal study. Nabizadeh F, Pirahesh K, Valizadeh P. J Neurol; 2022 Sep 01; 269(9):4836-4845. PubMed ID: 35426534 [Abstract] [Full Text] [Related]
44. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. Kester MI, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C, Scheltens P, van der Flier WM, Morris JC, Holtzman DM, Fagan AM. Alzheimers Res Ther; 2015 Sep 17; 7(1):59. PubMed ID: 26383836 [Abstract] [Full Text] [Related]
45. Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study. Brockmann K, Schulte C, Deuschle C, Hauser AK, Heger T, Gasser T, Maetzler W, Berg D. Parkinsonism Relat Disord; 2015 Dec 17; 21(12):1427-34. PubMed ID: 26475624 [Abstract] [Full Text] [Related]
48. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Vos SJ, van Rossum IA, Verhey F, Knol DL, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Frisoni GB, Froelich L, Nobili F, van der Flier W, Blennow K, Wolz R, Scheltens P, Visser PJ. Neurology; 2013 Mar 19; 80(12):1124-32. PubMed ID: 23446677 [Abstract] [Full Text] [Related]
49. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. van Rossum IA, Visser PJ, Knol DL, van der Flier WM, Teunissen CE, Barkhof F, Blankenstein MA, Scheltens P. J Alzheimers Dis; 2012 Mar 19; 29(2):319-27. PubMed ID: 22233766 [Abstract] [Full Text] [Related]
50. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease. Haris M, Yadav SK, Rizwan A, Singh A, Cai K, Kaura D, Wang E, Davatzikos C, Trojanowski JQ, Melhem ER, Marincola FM, Borthakur A. Neuroimage Clin; 2015 Mar 19; 7():598-604. PubMed ID: 25844314 [Abstract] [Full Text] [Related]
51. Role of cerebrospinal fluid biomarkers to predict conversion to dementia in patients with mild cognitive impairment: a clinical cohort study. Tondelli M, Bedin R, Chiari A, Molinari MA, Bonifacio G, Lelli N, Trenti T, Nichelli P. Clin Chem Lab Med; 2015 Feb 19; 53(3):453-60. PubMed ID: 25274948 [Abstract] [Full Text] [Related]
52. Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. Sierra-Rio A, Balasa M, Olives J, Antonell A, Iranzo A, Castellví M, Bosch B, Grau-Rivera O, Fernandez-Villullas G, Rami L, Lladó A, Sánchez-Valle R, Molinuevo JL. Neurodegener Dis; 2016 Feb 19; 16(1-2):69-76. PubMed ID: 26560503 [Abstract] [Full Text] [Related]
53. Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson's disease. Kandiah N, Zhang A, Cenina AR, Au WL, Nadkarni N, Tan LC. Parkinsonism Relat Disord; 2014 Nov 19; 20(11):1145-8. PubMed ID: 25176439 [Abstract] [Full Text] [Related]
54. Olfactory and cognitive decrements in 1991 Gulf War veterans with gulf war illness/chronic multisymptom illness. Chao LL. Environ Health; 2024 Jan 30; 23(1):14. PubMed ID: 38291474 [Abstract] [Full Text] [Related]
55. Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease: a 3 year longitudinal study. Baba T, Kikuchi A, Hirayama K, Nishio Y, Hosokai Y, Kanno S, Hasegawa T, Sugeno N, Konno M, Suzuki K, Takahashi S, Fukuda H, Aoki M, Itoyama Y, Mori E, Takeda A. Brain; 2012 Jan 30; 135(Pt 1):161-9. PubMed ID: 22287381 [Abstract] [Full Text] [Related]
56. Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles. Lerche S, Schulte C, Srulijes K, Pilotto A, Rattay TW, Hauser AK, Stransky E, Deuschle C, Csoti I, Lachmann I, Zetterberg H, Liepelt-Scarfone I, Gasser T, Maetzler W, Berg D, Brockmann K. Mov Disord; 2017 Dec 30; 32(12):1780-1783. PubMed ID: 29094781 [Abstract] [Full Text] [Related]
57. Smell identification function as a severity and progression marker in Alzheimer's disease. Velayudhan L, Pritchard M, Powell JF, Proitsi P, Lovestone S. Int Psychogeriatr; 2013 Jul 30; 25(7):1157-66. PubMed ID: 23597130 [Abstract] [Full Text] [Related]
58. [Subtypes of mild cognitive impairment in Parkinson's disease and factors predicting its becoming dementia]. Toribio-Diaz ME, Carod-Artal FJ. Rev Neurol; 2015 Jul 01; 61(1):14-24. PubMed ID: 26108904 [Abstract] [Full Text] [Related]
59. Proprioceptive and olfactory deficits in individuals with Parkinson disease and mild cognitive impairment. Li KY, Pickett KA, Fu HW, Chen RS. Acta Neurol Belg; 2024 Apr 01; 124(2):419-430. PubMed ID: 37962784 [Abstract] [Full Text] [Related]
60. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, Pratico D, Saint Louis LA, Wallin A, Blennow K, de Leon MJ. Neurobiol Aging; 2009 May 01; 30(5):682-90. PubMed ID: 17889968 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]